Akoya Biosciences, Inc.. (12/28/22). "Press Release: Akoya to Participate at 41st Annual J.P. Morgan Healthcare Conference". Marlborough, MA.

	Organisation	Akoya Biosciences Inc., Menlo Park
	Group	Akoya Biosciences (Group)
	Organisation 2	J.P. Morgan Securities LLC
	Group	JPMorgan Chase (Group)
	Product	J.P. Morgan 41st Annual Healthcare Conference 2023 San Francisco
	Index term	Akoya Biosciences–JPMorgan Chase: investor conference, 202301 supply service Akoya presents at JP Morgan Healthcare Conference 2023
	Person	McKelligon, Brian (Akoya Biosciences 201810 CEO)
	Person 2	Shah, Priyam (Akoya BIosciences 202212 Senior Director Investor Relations)

Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will be participating in the 41st Annual J.P. Morgan Healthcare Conference.

Brian McKelligon, CEO, is scheduled to present on Wednesday, January 11th, 2023 at 9:45 a.m. PT.

A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:

Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com

Media Contact:

Christine Quern
(617) 650-8497
media@akoyabio.com

Record changed: 2024-01-06